In response to recent case reports of retained gastric contents and pulmonary aspiration during sedation for endoscopic procedures or general anaesthesia in people with diabetes and/or obesity treated with GLP-1 receptors agonists (GLP-1RAs), a clinical practice recommendation regarding the periprocedural use of GLP-1RAs/GIP Receptor Agonists (GIPRAs) has been co-authored by representatives from the Australian Diabetes Society (ADS), National Association of Clinical Obesity Services (NACOS), Gastroenterological Society of Australia (GESA) and Australian and New Zealand College of Anaesthetists (ANZCA). The below represents a consensus based on review of currently available evidence and consensus expert opinion. Although the current level of evidence is weak to inform a guideline, this document was written to mitigate the risk of pulmonary aspiration with the periprocedural use of GLP-1RAs/GIPRAs which, although rare, is potentially fatal.
